GlassScriptPhysician profile
Benjamin M Zussman
NPI 1932468063
$2,404.52
in general payments reported to CMS, 2019-2025
25 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.93 · 2020: $19.45 · 2021: $115 · 2022: $685 · 2023: $1,066 · 2024: $308 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $481.46 | 2022-2023 | Artemis, Red 72, Penumbra System |
| Medtronic, INC. | $443.34 | 2021-2023 | Reacttm, Strata, Pipeline |
| Stryker Corporation | $297.96 | 2023-2025 | Surpass Evolve, Target, Na |
| Depuy Synthes Sales INC. | $259.52 | 2022-2023 | Cerepak Uniform |
| Cvrx, INC. | $224.40 | 2022 | |
| Irras USA, INC. | $119.20 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $65.93 | 2022-2024 | Andexxa |
| Cerapedics INC. | $57.41 | 2024 | I-Factor Peptide Enhanced Bone Graft |
| Qapel Medical INC | $47.76 | 2024 | |
| Glaxosmithkline, LLC. | $45.81 | 2023-2025 | Ojjaara |
| Microvention, INC. | $36.66 | 2023 | Lvis Junior, Stent, Headway Advanced Soft |
| Regeneron Healthcare Solutions, INC. | $35.66 | 2025 | Libtayo |
| Nuvasive, INC. | $34.53 | 2021 | |
| Abbvie INC. | $33.40 | 2024 | |
| Karyopharm Therapeutics INC. | $30.21 | 2024-2025 | Xpovio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $25.39 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $24.65 | 2023 | Orserdu |
| Convatec INC. | $23.51 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.41 | 2024 | Iclusig |
| Cardinal Health 200 LLC | $19.45 | 2020 | |
| Daiichi Sankyo INC. | $19.30 | 2025 | Datroway |
| Janssen Biotech, INC. | $17.27 | 2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $15.11 | 2024 | Krazati |
| Medtronic USA, INC. | $13.93 | 2019 | |
| Scientia Vascular | $11.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Zussman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.